|Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.|
|PMID: 20684825 Owner: NLM Status: MEDLINE|
|OBJECTIVE: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients.
METHODS: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up.
RESULTS: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8+/-4.6 microg/mL at baseline to 10.3+/-6.9 microg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE.
CONCLUSION: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.
|Taiki Ohashi; Rei Shibata; Takeshi Morimoto; Masaaki Kanashiro; Hideki Ishii; Satoshi Ichimiya; Takafumi Hiro; Katsumi Miyauchi; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Takeshi Kimura; Hiroyuki Daida; Toyoaki Murohara; Masunori Matsuzaki|
Related Documents :
|19556725 - Low incidence of cardiac events in statin-administered patients in cag study.
12542895 - Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with ang...
3608115 - Relation of parental history of early myocardial infarction to the level of apoprotein ...
25296565 - Experimental evaluation of myocardial fibrosis in a rapid atrial pacing model in new ze...
18394025 - Nitric oxide depresses connexin 43 after myocardial infarction in mice.
9707265 - Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, a...
|Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-05-11|
|Title: Atherosclerosis Volume: 212 ISSN: 1879-1484 ISO Abbreviation: Atherosclerosis Publication Date: 2010 Sep|
|Created Date: 2010-09-03 Completed Date: 2010-12-28 Revised Date: 2012-04-09|
Medline Journal Info:
|Nlm Unique ID: 0242543 Medline TA: Atherosclerosis Country: Ireland|
|Languages: eng Pagination: 237-42 Citation Subset: IM|
|Copyright 2010 Elsevier Ireland Ltd. All rights reserved.|
|Department of Cardiology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.|
|Data Bank Information|
Bank Name/Acc. No.:
|APA/MLA Format Download EndNote Download BibTex|
Acute Coronary Syndrome
Adiponectin / blood
Angioplasty, Balloon, Coronary / adverse effects*
Biological Markers / blood
Cardiovascular Diseases / blood, etiology*
Cholesterol, HDL / blood
Coronary Vessels / drug effects*, ultrasonography
Heptanoic Acids / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Pyrroles / therapeutic use*
Quinolines / therapeutic use*
Triglycerides / blood
|0/ADIPOQ protein, human; 0/Adiponectin; 0/Biological Markers; 0/Cholesterol, HDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 0/Quinolines; 0/Triglycerides; 110862-48-1/atorvastatin; 147511-69-1/pitavastatin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed b...
Next Document: Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion develo...